Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GX-188E in HPV-positive CIN2/3
NCT02596243Phase 2Unknown
- Sponsor
- Genexine
- Start
- Aug 2015
- Primary completion
- Mar 2018
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 3
01
Overview
A Phase 2 trial of tirvalimogene teraplasmid in cervical intraepithelial neoplasia (CIN), sponsored by Genexine. Status: unknown.
02
Drugs
tirvalimogene teraplasmid
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT02596243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02596243.